Home › NCT06288256

Neurocognitive and Genomic Predictors of Persistent Pain and Opioid Misuse After Spine Surgery

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age over 18
* With diagnoses of lumbar, cervical or thoracic spine pathology, scheduled to undergo elective spine surgery with or without instrumentation

Exclusion Criteria:

* Severe psychiatric condition interfering with study participation Any major cardiac, pulmonary, renal, infectious, hepatic condition that interferes with study participation
* Polytrauma
* Prolonged hospitalization (\>10days)
* Pregnancy
* Known surgery cancellation within study period

About the study

Having spine surgery and recovery is a vulnerable period when opioid naive patients may transition into long-term use of opioids, and when previously opioid tolerant patients may be at risk to continue towards long-term opioid use and dependence. However, little is known about risk for developing opioid misuse, taking opioids differently than indicated or prescribed, and later OUD. This study addresses the question of whether behavior, cognitive features, and genomic markers can predict misuse of opioids, persistent pain and disability in individuals after spine surgery.

To determine if impulsivity, inhibitory control, drug choice, and/or cognitive distortions predict opioid misuse and disability in spine surgery patients with differential gene expression.

This is a prospective observational longitudinal study characterizing behavioral phenotypes in adults undergoing spine surgery using both patient-reported survey measures, cognitive testing and blood sampling. Outcome measures include correlations between impulsivity measures, opioid drug choice responses and cognitive distortion scores, and opioid misuse with spine related disability, and gene expression counts.

What is being tested

• No Intervention (other)

Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 60 · Started: Mar 27, 2023

Contact the study team

• Chinwe Nwaneshiudu, MD PhD · Phone: 212-241-4203

Official record on ClinicalTrials.gov — NCT06288256

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.